Reactome | EPOR binds EPOR agonists

EPOR binds EPOR agonists

Stable Identifier

R-HSA-9709454

Type

Reaction [binding]

Species

Homo sapiens

Compartment

plasma membrane, extracellular region

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. EPO binds to the erythropoietin receptor (EPOR) and triggers the JAK2/STAT5 signalling cascade which ultimately signals the activatation of nuclear target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. The inhibition of apoptosis is critical in erythroid differentiation. EPO also activates other intracellular proteins involved in erythroid cell proliferation and survival.

The PEGylated functional analogue of EPO (peginesatide) and recombinant EPO forms (the epoetins) are used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy and chemotherapy (Bennet et al. 2004, Singh et al. 2006, Besarab et al. 2012, Zabaneh et al. 2015, Fishbane & Shah 2015, Zadeh 2017)

Literature References

PubMed ID	Title	Journal	Year
28142147	History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology Kalantar-Zadeh, K	Am J Nephrol	2017
24584613	Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis Zabaneh, R, Roger, SD, El-Shahawy, M, Roppolo, M, Runyan, G, O'Neil, J, Qiu, P	Perit Dial Int	2015
15459301	Pure red-cell aplasia and epoetin therapy Bennett, CL, Luminari, S, Nissenson, AR, Tallman, MS, Klinge, SA, McWilliams, N, McKoy, JM, Kim, B, Lyons, EA, Trifilio, SM, Raisch, DW, Evens, AM, Kuzel, TM, Schumock, GT, Belknap, SM, Locatelli, F, Rossert, J, Casadevall, N	N Engl J Med	2004
17108343	Correction of anemia with epoetin alfa in chronic kidney disease Singh, AK, Szczech, L, Tang, KL, Barnhart, H, Sapp, S, Wolfson, M, Reddan, D, CHOIR Investigators, -	N Engl J Med	2006
22935486	An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients Besarab, A, Zeig, SN, Martin, ER, Pergola, PE, Whittier, FC, Zabaneh, RI, Schiller, B, Mayo, M, Francisco, CA, Polu, KR, Duliege, AM	BMC Nephrol	2012
25582283	The emerging role of biosimilar epoetins in nephrology in the United States Fishbane, S, Shah, HH	Am J Kidney Dis	2015